Physician profile
Lisa Miller
NPI 1093049173
$10,799.64
in general payments reported to CMS, 2019-2025
44 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what 97% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,427 · 2022: $1,863 · 2023: $2,112 · 2024: $1,767 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,400 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,399.85 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.33 | 2021-2025 | |
| Sk Life Science, INC. | $847.31 | 2021-2025 | Xcopri |
| Amgen INC. | $674.35 | 2021-2025 | Uplizna, Repatha |
| Astrazeneca Pharmaceuticals Lp | $481.26 | 2021-2025 | Lokelma, Farxiga |
| Emd Serono, INC. | $415.20 | 2021-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $385.24 | 2021-2025 | Fintepla, Nayzilam, Briviact |
| Biohaven Pharmaceuticals, INC. | $348.07 | 2021 | |
| Horizon Therapeutics Plc | $338.71 | 2022-2023 | Uplizna |
| Janssen Pharmaceuticals, INC | $328.63 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $323.98 | 2021-2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $313.92 | 2022-2025 | Cobenfy, Zeposia |
| Argenx US, INC. | $297.36 | 2023-2025 | Vyvgart |
| Nevro Corp. | $286.94 | 2022 | |
| Neurocrine Biosciences, INC. | $273.04 | 2021-2023 | Ingrezza |
| Coloplast Corp | $268.22 | 2024-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.